Trazodone - Its multifunctional mechanism of action and clinical use;A trazodon multifunkcionális hatásmechanizmusa és klinikai alkalmazása

Neuropsychopharmacologia Hungarica

Volumn 12, Issue 4, 2010, Pages 477-482

  Frecska, Ede ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Alcohol dependence; Anxiety; Benzodiazepine dependence; Depression; Insomnia

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; TRAZODONE;

ALCOHOLISM; CHRONIC PAIN; DEPRESSION; DRUG ACTIVITY; DRUG INDICATION; DRUG MECHANISM; DRUG TOLERABILITY; DRUG USE; GENERALIZED ANXIETY DISORDER; HUNGARY; REVIEW;

EID: 78651367424     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Ansseau, M. and DeRoeck, J. (1993). Trazodone in benzodiazepine dependence. J Clin Psychiatry 54:189-191.
2. Burke, M.J. and Preskorn, S.H. (1995). Short-term treatment of mood disorders with standard antidepressants. In Bloom, F.E. and Kupfer, D.J. (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, pp 1053-1065.
3. Caccia, S., Ballabio, M., Samanin, R., Zanini, M.G. and Garattini, S. (1981). m-Chlorophenyl-piperazine, a central 5-hydroxytryptamine agonist, is a metabolite of trazodone. J Pharm Pharmacol 33:477-478.
4. Catanese, B. and Lisciani, R. (1970). Investigations on the absorption and distribution of trazodone or AF1161 in rats, dogs and humans. Boll Chim Farm 109:369-373.
5. Celada, P., Puig, M., Amargós-Bosch, M., Adell, A. and Artigas, F. (2004). The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29:252-265.
6. Conn, P.J. and Sanders-Bush, E. (1987). Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther 242:552-557.
7. Cusack, B., Nelson, A. and Richelson, E. (1994). Binding of antidepressants to human brain receptors: focus on newer generation compounds. Psychopharmacology (Berl) 114:559-565.
8. DeMeester, A., Carbutti, G., Gabriel, L. and Jacques, J.M. (2001). Fatal overdose with trazodone: case report and literature review. Acta Clin Belg 56:258-261.
9. Fink, H.A., MacDonald, R., Rutks, I.R. and Wilt TJ. (2003). Trazodone for erectile dysfunction: a systematic review and meta-analysis. BJU Int 92:441-446.
10. Garattini, S. (1974). Biochemical studies with trazodone: a new psychoactive drug. Mod Probl Pharmacopsychiatry 9:29-46.
11. Gershon, S. (1984). Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population. Psychopathology 17(suppl 2):39-50.
12. Griffiths, R.R. and Johnson, M.W. (2005). Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 66(suppl 9):31-41.
13. Haria, M., Fitton, A. and McTavish, D. (1994). Trazodone: a review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs Aging 4:331-355.
14. Ishida, M., Otani, K., Kaneko, S., Ohkubo, T., Osanai, T., Yasui, N., Mihara, K., Higuchi, H. and Sugawara, K. (1995). Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 10:143-146.
15. Janiri, L., Hadjichristos, A., Buonanno, A., Rago, R., Mannelli, P. and DeRisio, S. (1998). Adjuvant trazodone in the treatment of alcoholism: an open study. Alcohol Alcohol 33:362-365.
16. Kasper, S., Olivieri, L., Di Loreto, G. and Dionisio, P. (2005). A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin 21:1139-1146.
17. Liebowitz, N.R. and El-Mallakh, R.S. (1989). Trazodone for the treatment of anxiety symptoms in substance abusers. J Clin Psychopharmacol 9:449-451.
18. Marek, G.J., McDougle, C.J., Price, L.H. and Seiden, L.S. (1992). A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl) 109:2-11.
19. Monteleone, P. and Delrio, G. (1993). Pharmacokinetic and pharmacodynamic characteristics of a controlled-release formulation of trazodone versus the conventional formulation in healthy volunteers. Ital J Neurol Sci 14:443-449.
20. Munizza, C., Olivieri, L., Di Loreto, G. and Dionisio, P. (2006). A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 22:1703-1713.
21. Nierenberg, A.A., Adler, L.A., Peselow, E., Zornberg, G. and Rosenthal, M. (1994). Trazodone for antidepressant-associated insomnia. Am J Psychiatry 151:1069-1072.
22. Richelson, E. (1994): Pharmacology of antidepressants: characteristics of the ideal drug. Mayo Clin Proc 69:1069-1081.
23. Rickels, K., Schweizer, E., Garcia Espana, F., Case, G., DeMartinis, N. and Greenblatt, D. (1999). Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl) 141:1-5.
24. Rotzinger, S., Fang, J. and Baker, G.B. (1998). Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 26:572-575.
25. Salazar-Grueso, E.F., Rosenberg, R.S. and Roos, R.P. (1988). Sleep apnea in olivopontocerebellar degeneration: treatment with trazodone. Ann Neurol 23:399-401.
26. Savitz, J., Lucki, I. and Drevets, W.C. (2009). 5-HT1A receptor function in major depressive disorder. Prog Neurobiol 88:17-31.
27. Sheehan, D.V., Croft, H.A., Gossen, E.R., Levitt, R.J., Brullé, C., Bouchard, S. and Rozova, A. (2009). Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgmont) 6:20-33.
28. Silvestrini, B., Cioli, V., Burberi, S. and Catanese, B. (1968). Pharmacological properties of AF 1161, a new psychotropic drug. Int J Neuropharmacol 7:587-599.
29. Silvestrini, B. (1986). Trazodone and the mental pain hypothesis of depression. Neuropsychobiology 15(suppl 1):2-9.
30. Stahl, S.M. (2008). Stahl's Essential Psychopharmacology. New York, Cambridge University Press.
31. Stahl, S.M. (2009). Mechanism of action of trazodone: a multifunctional drug. CNS Spectr 14:536-546.
32. Subhash, M.N., Srinivas B.N. and Vinod, K.Y. (2002). Alterations in 5-HT1A receptors and adenylyl cyclase response by trazodone in regions of rat brain. Life Sci 71:1559-1567.
33. Sultzer, D.L., Gray, K.F., Gunay, I., Berisford, M.A. and Mahler, M.E. (1997). A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 5:60-69.
34. Tatsumi, M., Groshan, K., Blakely, R.D. and Richelson, E. (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340:249-258. (Pubitemid 28022649)
35. Ventafridda, V., Caraceni, A., Saita, L., Bonezzi, C., DeConno, F., Guarise, G., Ramella, G., Silvani, V., Tamburini, M. and Toscani, F. (1988). Trazodone for deafferentation pain: comparison with amitriptyline. Psychopharmacology (Berl) 95(suppl):S44-S49.